CHALLENGES AND POSSIBLE SOLUTIONS IN DETERMINING INR

Despite the development of new oral anticoagulants, vitamin K antagonists (VKA) continue to be widely used for the treatment and prevention of throm-boembolic complications. On top of that, they have no alternative in patients with artificial heart valves. Receiving AVC results in the synthesis of m...

Full description

Saved in:
Bibliographic Details
Main Authors: E. V. Titaeva (Author), A. B. Dobrovolsky (Author)
Format: Book
Published: «REMEDIUM GROUP» Ltd., 2015-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_cd36ab0324f34cf890b3dc0ef49644fc
042 |a dc 
100 1 0 |a E. V. Titaeva  |e author 
700 1 0 |a A. B. Dobrovolsky  |e author 
245 0 0 |a CHALLENGES AND POSSIBLE SOLUTIONS IN DETERMINING INR 
260 |b «REMEDIUM GROUP» Ltd.,   |c 2015-12-01T00:00:00Z. 
500 |a 2307-1109 
500 |a 2658-5952 
500 |a 10.21518/2307-1109-2015-2-107-114 
520 |a Despite the development of new oral anticoagulants, vitamin K antagonists (VKA) continue to be widely used for the treatment and prevention of throm-boembolic complications. On top of that, they have no alternative in patients with artificial heart valves. Receiving AVC results in the synthesis of modified factors of pro-thrombin-converting complex (prothrombin, factor X, IX and VII, as well as two components of the anticoagulant system - protein C and protein S) without capacity to bind with the phospholipid surface, which significantly reduces the likelihood of intravascular thrombosis, but the degree of anti-coagulation is individual and requires monitoring for each patient. Prothrombin test (PT test) is used to monitor the degree of anti-coagulation, which is based on determining the plasma clotting time in a patient after addition of thromboplastin and calcium chloride (prothrombin time). Tromboplastin is animal tissue extract containing tissue factor and phospholipids. In practice, the determination of the anti-coagulation degree by prothrombin time is no easy task. The fact of the matter is that various thromboplastin drugs have different sensitivity to the reduction of factors of prothrombin-converting complex; clotting time of normal and pathologic plasma depends on used thromboplastin and differs even for different series of thromboplastin supplied by the same manufacturer. In addition, prothrombin time depends on the method used (coagulometer). WHO had adopted a system of reporting the PT test results in the form of INR (International normalized ratio) specifically to measure the degree of anti-coagulation in patients who receive oral anticoagulant therapy. 
546 |a RU 
690 |a антагонисты витамина к 
690 |a протромбиновый комплекс 
690 |a тромбопластин 
690 |a степень коагуляции 
690 |a коагулометр 
690 |a Internal medicine 
690 |a RC31-1245 
655 7 |a article  |2 local 
786 0 |n Атеротромбоз, Vol 0, Iss 2, Pp 107-114 (2015) 
787 0 |n https://www.aterotromboz.ru/jour/article/view/53 
787 0 |n https://doaj.org/toc/2307-1109 
787 0 |n https://doaj.org/toc/2658-5952 
856 4 1 |u https://doaj.org/article/cd36ab0324f34cf890b3dc0ef49644fc  |z Connect to this object online.